Desferrioxamine (DFO), a siderophore initially isolated from Streptomyces pilosus, possesses extraordinary metal binding properties with wide biomedical applications that include chelation therapy, nuclear imaging, and antiproliferation. In this work, we prepared a novel multifunctional agent consisting of (i) a near-infrared (NIR) fluorescent probe-cypate; (ii) an integrin R v 3 receptor (ABIR)-avid cyclic RGD peptide, and (iii) a DFO moiety, DFO-cypate-cyclo[RGDfK(∼)] (1, with ∼ representing the cypate conjugation site at the side chain of lysine; f is D-phenylalanine). Compound 1 and two control compounds, cypate-cyclo[RGDfK(∼)] (2) and cypate-DFO (3), were synthesized by modular assembly of the corresponding protected RGD peptide cyclo[R(Pbf)GD(OBut)fK] and DFO on the dicarboxylic acid-containing cypate scaffold in solution. The three compounds exhibited similar UV-vis and emission spectral properties. Metal binding analysis shows that DFO as well as 1 and 3 exhibited relatively high binding affinity with Fe(III), Al(III), and Ga(III). In contrast to Ga(III), the binding of Fe to 1 and 3 quenched the fluorescence emission of cypate significantly, suggesting an efficient metal-mediated approach to perturb the spectral properties of NIR fluorescent carbocyanine probes. In vitro, 1 showed a high ABIR binding affinity (10 -7 M) comparable to that of 2 and the reference peptide cyclo(RGDfV), indicating that both DFO and cypate motifs did not interfere significantly with the molecular recognition of the cyclic RGD motif with ABIR. Fluorescence microscopy showed that internalization of 1 and 2 in ABIR-positive A549 cells at 1 h postincubation was higher than 3 and cypate alone, demonstrating that incorporating ABIR-targeting RGD motif could improve cellular internalization of DFO analogues. The ensemble of these findings demonstrate the use of multifunctional NIR fluorescent ABIR-targeting DFO analogues to modulate the spectral properties of the NIR fluorescent probe by the chelating properties of DFO and visualize intracellular delivery of DFO by receptor-specific peptides. These features provide a strategy to explore the potential of 1 in tumor imaging and treatment as well as some molecular recognition processes mediated by metal ions.
INTRODUCTION
Recent research efforts have demonstrated that molecular imaging is a powerful tool for localizing, identifying, and characterizing a host of disease-specific targets. Examples include imaging molecular interactions, cell trafficking, tumor vitality, cell proliferation, apoptosis, angiogenesis, and response to treatment. In particular, optical molecular imaging holds great promise to accelerate drug discovery and development, including compound screening, lead discovery, optimization, pharmacokinetic studies, and clinical trials (1) (2) (3) .
An attractive feature of optical imaging is its ability to unravel the molecular basis of cancers and other diseases, thereby providing vital information for diagnosing, staging, and monitoring therapeutic response (4) (5) (6) . These applications emanate from numerous advantages of optical methods, including high detection sensitivity, real-time monitoring, convenience, and accessibility. In contrast to other established imaging methods such as radionuclear and X-ray-computed tomography, the use of low-energy (nonionizing) radiation for optical imaging provides additional benefit, especially in longitudinal studies. Over the past few years, tremendous progress has been made in the development of optical contrast agents for in vivo tumor optical imaging. For instance, we and others have developed NIR fluorescent probes such as cyanine dyes and their bioconjugates, including somatostatin and RGD peptide analogues, as optical contrast agents for in vitro and in vivo tumor optical imaging (7) (8) (9) (10) (11) (12) (13) . These results have inspired us to further apply optical imaging and related optical contrast agents in the discovery and development of novel, multifunctional, and targeted oncologic drugs. For example, the biological properties of therapeutic agents such as desferrioxamine (DFO) can be altered by linkage to a target-specific NIR fluorescent probe and the intracellular transport visualized by optical methods.
DFO, a siderophore initially isolated from Streptomyces pilosus, is a selective iron chelator (14) . This siderphore and some analogues have been used in chelation therapy to treat iron-overload diseases, such as thalassemia, sickle-cell anemia, and hemochromatosis (15) (16) (17) . DFO has also been shown to possess antiproliferative activities, and clinical studies have demonstrated its potential as an adjunct to chemotherapy regimens (18) (19) (20) (21) . Its radiosensitizing activities have been utilized in radiation oncology (22) . DFO has also served as a good chelator for radioactive metals in cancer nuclear imaging as demonstrated by the use of radioactive 67 Ga/ 68 Ga-[DFO]-octreotide to image somatostatin receptor-positive tumors by positron emission tomography (23) . Despite its lack of oral bioavailability and difficulties in patient compliance, the continued use of DFO in clinical settings strongly attests to its great potential in biomedical applications. It further suggests the potential use of DFO as a lead compound for discovering and developing novel DFO analogues and synthetic mimetics with improved biological properties and activities (24) (25) (26) (27) . However, the biological activity of DFO is not targeted to a specific molecular process and its hydrophilic nature limits its internalization in cells. For these reasons, conjugation of DFO with a receptor-specific ligand such as R V 3 integrin receptor (ABIR)-avid RGD peptide could overcome these problems.
Integrins are heterodimeric cell-surface receptors that mediate cell-cell and cell-matrix adhesion, metastasis, and angiogenesis processes (28) (29) (30) (31) . In particular, the overexpression of ABIR on activated endothelial cells in the neovasculature of tumors such as breast cancer, lung carcinomas, melanomas, and glioblastomas has been correlated with tumor growth, invasion, and metastasis. Therefore, ABIR is an attractive molecular target for tumor imaging, early diagnosis, and therapy (32) (33) (34) (35) (36) (37) . Diverse ligands, including peptides and peptidomimetics have been found to interact with ABIR. Some of the high ABIR-binding peptides have been successfully used to elucidate the structure and mechanisms as well as targeted delivery of NIR fluorescent probes, radionuclides, and anticancer agents (38) (39) (40) (41) (42) (43) (44) .
In this study, we report the synthesis and in vitro evaluation of 1 and its two analogues, that is, cypate-[RGDfK(∼)] (2) and cypate-DFO (3) for targeting ABIR (Figure 1 ). The RGD peptide in the novel multifunctional NIR fluorescent RGD-bearing DFO (1) enhanced the cellular uptake of DFO. We also found that the metal-chelating properties of DFO can modulate the NIR fluorescence emission of cypate.
EXPERIMENTAL PROCEDURES
General. All reagents and solvents were purchased from commercial sources. Solvents and chemicals were reagent grade and used without further purification. Cypate was prepared as previously reported (45) . Analytical (Vydac C-18 column; 250 × 4.6 mm) and semipreparative (Vydac C-18 column; 25 × 2.2 cm) HPLC were performed at a flow rate of 1.0 mL/min and 9.5 mL/min, respectively. HPLC solvents consisted of solvent A (water containing 0.05% trifluoroacetic acid (TFA)) and solvent B (acetonitrile (ACN) containing 0.05% TFA). Linear gradient elution protocol for analytical HPLC started from 90% A to 30% A in B for 20 min. The gradient for semipreparative HPLC ranged from 90% A to 30% A over 15 min and was held at 30% for 30 min. The elution profile was monitored by UV/vis at 214 and 254 nm. Mass spectra (ES-MS) were obtained using a Shimadzu mass spectrometer (LCMS-2010A) in the positive electrospray mode.
Solid Phase Peptide Synthesis. All the peptides were assembled manually on resin using conventional Fmoc chemistry by column chromatography (silica gel, methanol/dichloromethane) to afford the desired compound (295 mg, 60% yield; ES-MS: [MH] + 912.3). 2+ 759.8) and split into two portions, one of which was dissolved in a mixture of TFA/water (95:5) and deblocked for 4 h. The TFA mixture was added to cold methyl tert-butyl ether (MTBE, 10 mL). Finally, the solid precipitate was collected by filtration and purified by HPLC to afford the desired product cypate-cyclo 
Cypate-DFO (3).
Deferoxamine mesylate salt (131 mg, 0.2 mmol) was dissolved in DMSO (3 mL) in the presence of DIEA (26 mg, 0.2 mmol) by sonication, followed by the addition of HOBT (27 mg, 0.2 mmol), cypate (141 mg, 0.2 mmol), and EDCI (38 mg, 0.2 mmol). The mixture was stirred at room temperature for 2 h and added with stirring to ether. The precipitate was collected by filtration, one-third of which was purified by HPLC to afford cypate-DFO (25 mg, 30%; ES-MS:
Absorption and Emission Spectral Analysis. Absorption and fluorescence spectra were recorded on a DU 640 UV-visible spectrophotometer and Fluorolog-3 fluorometer, respectively. Stock solutions (1.0 mM) were prepared by dissolving each sample in 80% aq DMSO, unless otherwise stated. UV-vis and fluorescence measurements were carried out by sequentially adding 5.0 µL aliquots of the stock solutions via a micropipette into 3 mL of 20% aq DMSO solution in a quartz cuvette. The fluorescence quantum yields of 1, 2, 3, cypate, and ICG in DMSO were determined according to an established protocol and referenced to ICG in DMSO (Q.Y. ) 0.13). The absorbance of five serial dilutions of each compound was measured in the concentration range between 0.1 and 1.0 µM. The quantum yield (Φ) was determined according to the following equation (47):
where the subscripts s and r refer to sample and reference ICG (obtained by HPLC purification of commercially available ICG from Aldrich), respectively. η represents the refractive index of the solvent, and q represents a correction factor for the excitation wavelength used. q s /q r was assumed to be 1 under similar excitation conditions. Metal Binding Studies. Stock solutions (1 mM) of compounds 1, 3, and DFO were first prepared with 50% aq ACN. We also prepared stock solutions (1 mM) of the following metal salts in distilled water: Fe(NO 3 ) 3 ABIR Binding Affinity. Receptor binding assays were performed by using human-purified ABIR protein from Chemicon International, Inc. (Temecula, CA) using the method reported previously (48) . Briefly, assays were carried out in the Millipore Duropore membrane 96-well plates and the Millipore MultiScreen system (Bedfore, MA).
125 I-echistatin was purchased from Amersham Biosciences (Piscataway, NJ). The specific activity of the radiolabeled peptide was ∼2000 Ci/mmol. Radiochemical purity (90%) was determined by reverse-phase HPLC. The 96-well membrane plate was blocked with 0.1% polyethylenimine blocking solution overnight at 4°C.
125 Iechistatin (50 nmol/L) was added to the binding buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 , and 1% BSA) containing integrin ABIR protein (50 ng per well in 96-well membrane plate) and ligands in a total volume of 200 µL per well. The concentration range of ligand was between 0.01 µM and 100 µM. The mixtures were incubated for 2 h at room temperature, filtered by centrifugation at 1500g, and washed with 0.20 mL of ice-cold binding buffer (3×). The filters containing radioactivity-bound ABIR were removed using a punch apparatus and counted using a Packard Cobra II Autogamma counter (Meriden, CT). Nonspecific binding of 125 I-echistatin was between 5 to 10% of the total binding. The 50% inhibitory concentrations (IC 50 ) were calculated by nonlinear regression analysis using GraphPad Prism 4 data fitting software (GraphPad Software, Inc., San Diego, CA). Three independent binding assays were performed in triplicate per sample.
Cell Culture. The human nonsmall cell carcinoma cell line A549 is widely used to study the role of integrins in normal and pathophysiological processes. These cells were purchased from ATCC and grown in 75 cm tissue culture flasks or on Laboratory-Tek chambered slides in Ham's F12K medium with 2 mM L-glutamine supplemented with 1.5 g/L sodium bicarbonate, 10% fetal calf serum, 100 units/mL penicillin, and 100 units/ mL streptomycin under humidified atmosphere containing 5% CO 2 at 37°C.
Internalization and Fluorescence Microscopy. A549 cells were grown on Laboratory-Tek slides. The culture medium was replaced, and the cells were incubated for different times up to 24 h at 37°C in the presence of the cypate-labeled DFO probes (1 µM in 0.02% DMSO). After treatment, cells were washed (3×) with PBS containing 1 mM CaCl 2 and mounted with Prolong Gold containing DAPI mounting medium and coverslipped (Invitrogen). For fluorescence microscopy, cells were visualized with an Olympus FV1000 microscope using a 60X/ 1.20M, 0.13-0.21 NA water immersion objective. Fluorescence emission was detected from 805-830 nm using a 780 nm laser at 100% transmission for excitation. Images of each group of slides were acquired with the same microscope settings during a single imaging session, allowing for qualitative comparison of the relative fluorescence. The relative fluorescence intensity of five regions of interest for each image was determined with Slidebook software from Olympus and the results averaged. The results were normalized to the average relative fluorescence of DFO-cypate treated cells.
For mitochondrial staining, 5 nm Mitotracker Green (Invitrogen) was added during the last 15 min of incubation. For lysosomal staining, cells were stained with anti-LAMP1 antibody as described in the literature (49) . Briefly, cells were fixed for 15 min with 4% paraformaldehyde for 15 min, after which they were washed 3× with PBS containing 1 mM CaCl 2 . Slides were incubated for 1 h at room temperature with 10% rabbit serum to block nonspecific binding after which they were incubated overnight at 4°C with 2 µg/mL anti-LAMP1 goat polyclonal IgG (Santa Cruz). After washing 3× with PBS, slides were incubated for 1 h at room temperature with 10 µg/mL Cy3 conjugated rabbit antigoat IgG (Zymed). After washing 3× with PBS, slides were mounted with Prolong Gold and coverslipped. Cells were visualized with an Olympus FV1000 microscope using a 60X/1.20M, 0.13-0.21 NA water immersion objective. Fluorescence emission was detected by using a 488 nm laser at 5% transmission and 500-600 nm emission (Mitotracker green) or by using a 543 nm laser at 15% transmission and 555-655 nm emission (LAMP-1).
RESULTS AND DISCUSSION
Molecular Design. Previously, we reported the synthesis and applications of a dicarboxylic acid-containing carbocyanine fluorophore (cypate) (10, 45) . The facile synthesis of cypate and its excellent NIR spectral properties have allowed us to conveniently label diverse peptides and other bioactive molecules with cypate in solution and on solid support. Particularly, the two carboxylic acid groups of cypate have facilitated its use as an optical scaffold to construct diverse bioactive NIR fluorescent molecular probes, such as monomeric,dimeric,macrocyclic,andmultivalentanalogues (8, 45, 50, 51) . Conjugation of cypate with small peptides that target specific cell-surface receptors, such as ABIR and the somatostatin receptor, allows site-specific targeting of diseased tissues for optical imaging (9, 10, 51) . In particular, previous reports have shown that cyclic RGD pentapeptide cyclo(RGDfV) and some of its analogues bind to ABIR with high affinity and selectivity. Further modification of the biological properties of cypate-labeled RGD peptides could be obtained by incorporating another bioactive molecule such as DFO.
The metal-binding properties and the related biological activities of DFO have been ascribed to its three hydroxamate groups (26, 52) . Therefore, the amino group of DFO provides a desirable site for its structural modification. In this work, we used cypate to construct a three-pronged architecture bearing both the DFO motif and ABIR-targeting RGD peptide (cyclo[RGDfK(∼)] (Figure 1 ). We anticipated that the new NIR fluorescent RGD-bearing DFO compound (1) would serve as a multifunctional platform for biomedical applications. For example, the RGD peptide motif could be used for the targeted delivery of DFO to ABIR positive tumors, while cypate serves as the optical antenna to track, visualize, and quantify the fate of 1 in cells and in vivo by NIR fluorescence imaging. In addition, the integration of DFO and RGD peptide into cypate could cooperatively enhance the related biological activities. Finally, the metal-binding DFO could modify the structure, function, and regulation of divalent, cation-dependent ABIR (28, 38) . Together, these potential applications of NIR fluorescent DFO compounds motivated the design, synthesis, and evaluation of the compounds described in this article. Spectral Properties. Stock solutions (1 mM) of the DFOcontaining compounds were prepared in DMSO, and spectral measurements were carried out by adding 5 µL aliquots of the stock solutions via a micropipette into 3 mL of DMSO solution in a quartz cuvette. All of the compounds showed similar spectral features, with minor spectral shifts in the absorption and emission maxima (Figure 2 ). The attachment of cyclo-[RGDfK(∼)] to cypate increased the molar absorptivity (ε) while the DFO attachment decreased ε (Table 1) . Compound 1 containing both DFO and cyclo[RGDfK(∼)] showed similar ε with cypate. Overall, conjugation of the highly hydrophilic DFO to cypate improved the water solubility of the dye without effect on its spectral properties.
Metal Binding Studies. Siderophores such as DFO are good ligands for Fe(III), and the biological activities of DFO are related to its metal-binding properties (20, (54) (55) (56) . Previous studies have shown that DFO and the related hydroxamate compounds also possess high binding affinities with Al(III) and Ga(III) (26, 53) . Therefore, we evaluated the metal-binding properties of 1 and the related effects on the corresponding optical properties of DFO-bearing fluorescent compounds. Because of its high sensitivity, we used ES-MS to study metal coordination with DFO, as described previously (26, 57) . This method is suitable for screening the relative metal-binding selectivity and affinity of some compounds, especially those in limited supply.
Compounds 1, 3, and DFO (100 µM in 50% aq acetonitrile) were screened for their binding with 13 different metal ions, Fe(III), Al(III), Ga(III), In(III), Gd(III), Cu(II), Zn(II), Co(II), Ni(II), Mn(II), Fe(II), Ca(II), and Mg(II), at 200 µM in water. All the three DFO-bearing compounds exhibited high binding affinity and selectivity for Ga(III), Al(III), and Fe(III) compared to the other metal ions. The ES-MS spectra of 1 and the metal chelates shown in Figure 3 are representative of the trend observed for these compounds. Compound 1 showed two typical doubly and triply charged peaks at 876.7 and 584.9 in its ES-MS spectrum. Upon metal binding, these peaks were replaced by the corresponding doubly charged (903.5, 889.0, and 910.1) and triply charged (602.2, 592.8, and 607.5) peaks of the resulting Ga(III), Al(III), and Fe(III) complexes, respectively. These peaks were correlated with the theoretical masses based
n+ , where L and M represent the molecular weight of a ligand and a metal, respectively. The high abundance of the desired metal chelate peaks with negligible residue from the starting DFO ligands strongly suggests the complete formation of 1:1 metal complexes in aq ACN.
We further calculated the relative metal-binding affinity (%) of each ligand as a percentage of the relative abundance of the metal-binding ligand peaks with the total ligand-related peaks in a positive ES-MS spectrum according to the following equation, as reported previously (26, 58) :
where L 2 and LFe 2 are the doubly charged peak abundance of a ligand and its complex, while L 3 and LFe 3 are the triply charged peak abundance of a ligand and its complex. The related peaks associated with the addition of sodium ions were also calculated. As shown in Figure 4 , the ES-MS analysis clearly demonstrated the relative metal binding selectivity and affinity with Fe(III), Fe(II), Ga(III), Al(III), and In(III). Despite their structural differences, the metal binding selectivity of 1, 3, and DFO was similar, indicating that the chelating property of DFO was maintained, independent of the molecular design.
In contrast to the ES-MS spectra of Ga(III) and Al(III), the addition of Fe(III) and Cu(II) resulted in complicated ES-MS spectra with multiple peaks around the doubly and triply charged peaks. This observation suggests that Cu(II) had weaker binding with 1, but might greatly impact the ionization of 1 and the stability of the resulting ions in gas phase. In addition, the low abundance of the related 1:1 ligand/metal complex indicates that Cu(II) binding might occur between two or more ligands of 1 with two or more Cu(II).
The relatively high binding affinity of DFO-bearing compounds with Fe(III), Al(III), and Ga(III) makes it possible to further functionalize 1 via metal binding. Therefore, we prepared and isolated the Ga(III) complex of 1 to demonstrate the feasibility of obtaining fluorescent DFO chelates. By mixing 1 with excess Ga(III) in aq ACN, the Ga(III) complex was obtained by HPLC purification and further characterized by ES-MS. The metal complex has a longer retention time than 1, suggesting that the coordination of Ga(III) by the three DFO hydroxamates reduces the hydrophilicity of 1 ( Figure 5 ). The successful preparation and characterization of the Ga(III) complex provide an exciting dimension for exploring additional applications of this compound in biomedicine.
Spectrally, there was no significant change in the green color of 1 upon the additions of the metals, with the exception of Fe(III), Fe(II), and Cu(II), where a change was observed ( Figure 6 ). Clearly, the addition of Cu(II) and Fe(III) markedly decreased the UV-vis absorption and quenched the fluorescence emission of 1 as shown in Figure 6 . On the basis of the ES-MS analysis discussed above, it is likely that spectral changes by these metals occurred by different mechanisms. While Cu (II) appears to quench fluorescence by interacting directly with the cypate motif, the stable Fe complex may quench fluorescence by the photoinduced electron transfer mechanism. In contrast to Fe(III) and Cu(II), Ga(III) binding did not significantly alter the UV-vis absorbance of 1. Interestingly, Ga(III) seemed to enhance light emission to some extent. This finding is in agreement with a previous study with 3, where a similar enhancement was observed (53) . Considering that a DFO chelate of radioactive Ga(III) has been used previously for nuclear imaging, the Ga(III)-mediated fluorescence enhancement favors the use of the Ga(III) complex of compounds 1 and 3 to develop a dual optical-nuclear imaging agent. In addition, the contrasting effects of Fe(III) and Ga(III) on the optical properties of cypate provide an efficient approach to perturb the spectral properties of NIR fluorescent carbocyanine probes via metal binding.
Receptor Binding Assays. Among the diverse RGD peptides that have been developed for targeting ABIR, the lactam-based cyclic penta-peptide cyclo(RGDfV) and its analogues are well known for their high binding affinity and selectivity with ABIR. In this study, commercially available ABIR-avid peptide cyclo(RGDfV) was used as a reference compound to study the effect of DFO on the ABIR binding affinity of 1 and 2. The IC 50 values of these compounds were determined by competitive inhibition of Echistatin binding to purified ABIR, as described previously (48, 59) . Echistatin is a polypeptide that binds irreversibly with high affinity and specificity to the ABIR and the radiolabeled analogue.
125 Iechistatin was used as a tracer in the binding assay. Compounds 1, 2, and cyclo(RGDfV) were found to have IC 50 values of 1.8 × 10 -7 M, 7.7 × 10 -8 M, and 4.1 × 10 -7 M, respectively. Under similar conditions, the presence of the DFO motif in 1 decreased the ABIR affinity of 2 by a factor of about 2, but the resulting affinity was comparable to that of the reference cyclic RGD compound. These findings indicate that the RGD peptide can modulate the biological activities of DFO through receptor-mediated delivery of this otherwise nonspecific drug to target tissue and cells.
Cell Internalization. Uptake and distribution of drugs and contrast agents in cells provide a key index for understanding the functions and predicting the in vivo behavior of fluorescent compounds. Therefore, labeling DFO with fluorescent dye allows the use of the resultant molecule as molecular probe for imaging DFO distribution in cells. Considering that the ABIR binding assay revealed the retention of RGD peptide binding affinity by 1, we assessed the internalization and subcellular distribution of 1, 2, and 3 in an ABIR-positive cell line, A549. The incubation of A549 cells with 3 (1 µM) in medium containing 0.02% DMSO showed minimal uptake of the compound, with normalized fluorescence similar to the back- ground signal (Figure 7) . Expectedly, hydrophilic molecules such as DFO have difficulty crossing the plasma membranes of cells without an active transport mechanism. In contrast, both 1 and 2 internalized rapidly within 1 h post incubation and remained in the intracellular space up to 10 h. The enhanced internalizations of 1 and 2 could be ascribed to the interaction of the RGD peptide with ABIR in the cell membranes. Thus, the RGD peptide provided an endocytotic pathway for DFO. At 1 h postincubation, the internalization of 1 and 2 in A549 cells was similar to each other, but the retention of 1 in the cells was lower at longer incubation times than that of 2 ( Figure  7D ). The differences in the internalization rate appear to correlate with their ABIR binding affinity, with 2 having higher affinity than 1. Once internalized, however, the rates of subsequent efflux of the two compounds from the cell were similar, with the intracellular fluorescence intensity for both compounds approaching background at 24 h post incubation. The fluctuations in fluorescence shown in Figure 7D could be attributed to changes in receptor density as a function of time.
On the basis of the dissimilarity in structural features, ABIR binding affinity, and internalization rates, we expected differences in the intracellular distribution of compounds 1, 2, and 3. Interestingly, once inside the cell, all three compounds appeared to localize in the mitochondria, the lysosomes, and the cytosol (Figures 8 and 9 ). The absence of identifiable uptake in the cell nuclei favors using the fluorescent DFO compounds as imaging agents because of the need to minimize nuclear translocation of imaging agents, thereby preventing the potential mutagenic effect on the cells.
CONCLUSIONS
We have developed a novel multifunctional molecular probe consisting of a metal-chelating DFO, a NIR fluorescent cypate, and an ABIR-avid cyclic RGD peptide. Each component synergistically contributes to the overall properties of new compound 1. Cypate provides a detectable signal for imaging purposes; the RGD peptide effectively delivers both cypate and DFO into cells; and metal-binding DFO efficiently modulates the optical properties of cypate. The impressive ABIR-mediated internalization of 1 in cells without permeating the cell nucleus is advantageous for imaging applications, where nuclear uptake can be detrimental to the cells and living organisms. This work represents our initial effort toward the discovery and development of novel ABIRtargeting DFO compounds for optical imaging. Specifically, 1 provides a multifunctional molecular platform for optimizing the structure, improving biological activities, exploring new applications, and understanding the mechanisms of action. The synthetic approach we used is amenable to combinatorial chemistry and the parallel synthesis of diverse NIR fluorescent DFO analogues.
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